← ANALYST RATINGS · TIPRANKS
Seaport Therapeutics, Inc. (SPTX): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $36.83, the highest $50.00, the lowest $28.00. The average is +106.6% from the last price of $17.83.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $28.00 | Buy | +57.0% | Initiated | 14.10.26on TipRanks 05:35 | +4.8%next day +5.2% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $29.00 → $32.00+10.3% | Buy | +79.5% | Reiterated | 12.10.26on TipRanks 09:50 | −5.4%next day −6.2% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $50.00 | Buy | +180.4% | Reiterated | 08.10.26on TipRanks 06:30 | +0.3%next day +0.7% · 5 days −1.5% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $35.00 | Buy | +96.3% | Reiterated | 07.10.26on TipRanks Oct 8 05:55 | +3.5%next day +0.3% · 5 days −6.0% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $46.00 | Buy | +158.0% | Initiated | 25.09.26on TipRanks Sep 28 00:35 | +1.4%next day −8.0% · 5 days −14.2% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $35.00 | Buy | +96.3% | Reiterated | 10.09.26on TipRanks 09:30 | +7.6%next day −0.6% · 5 days −6.9% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $32.00 | Buy | +79.5% | Reiterated | 10.09.26on TipRanks 09:26 | +7.6%next day −0.6% · 5 days −6.9% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $50.00 | Buy | +180.4% | Reiterated | 10.09.26on TipRanks 07:15 | +7.6%next day −0.6% · 5 days −6.9% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $30.00 | Buy | +68.3% | Reiterated | 13.08.26on TipRanks 11:35 | −1.1%next day +2.3% · 5 days +3.3% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | — | Hold | — | Initiated | 07.07.26on TipRanks 09:00 | −5.4%next day +16.9% · 5 days +11.6% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $42.00 | Buy | +135.6% | Reiterated | 08.06.26on TipRanks Jun 9 07:10 | −1.7%next day +9.3% · 5 days +5.5% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $35.00 | Buy | +96.3% | Initiated | 27.05.26on TipRanks 08:30 | +0.2%next day +3.6% · 5 days −5.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Seaport Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.60 at a price of $20.17 (+91.4%); now: $36.83 at $17.83 (+106.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 8 | 9 | 8 | 7 | 10 |
| Buy | 0 | 0 | 0 | 2 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Seaport Therapeutics, Inc.
- CEO: Daphne Zohar
- Employees: 58
- 101 Seaport Blvd., Boston, MA, 02210-2186, US
- www.seaporttx.com
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Data from the stock’s TipRanks forecast page, read 28 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗